NCT00421317 2026-03-13
O-Mel-Inib
Centre Oscar Lambret
Phase 2 Terminated
Clinical Trials
125 trialsNCT05493215 2026-02-17
Imatinib TDM in GIST
University of Kentucky
Phase 2 Recruiting
NCT05152472 2026-01-08
ATEZOGIST
Centre Leon Berard
Phase 2 Recruiting
NCT04626024 2025-12-19
TOKIN
Baylor College of Medicine
Phase 2 Recruiting
NCT04070443 2025-11-18
TIPI
Centre Leon Berard
Phase 2 Active not recruiting
NCT04598009 2025-09-03
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
University of California, San Francisco
Phase 2 Recruiting
NCT00015847 2025-08-22
Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT05385549 2025-08-08
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
Asan Medical Center
Phase 2 Recruiting
NCT04838041 2025-07-30
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Medical College of Wisconsin
Phase 2 Recruiting
NCT00476190 2025-06-12
ALL Adult Consortium Trial: Adult ALL Trial
Dana-Farber Cancer Institute
Phase 2 Completed
NCT06119789 2025-03-26
MATRIX-Rare
Oslo University Hospital
Phase 2 Recruiting
NCT01804985 2025-03-14
DESTINY
University of Liverpool
Phase 2 Completed
NCT03906292 2025-03-10
CMLXI
University of Jena
Phase 2 Active not recruiting
NCT04423185 2025-02-11
PLATFORM Study of Precision Medicine for Rare Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06692491 2024-11-18
SPRING
Peking University Shenzhen Hospital
Phase 2 Not yet recruiting
NCT02001818 2024-08-06
PInNACLe
Australasian Leukaemia and Lymphoma Group
Phase 2 Completed
NCT01541709 2024-01-02
Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI
Asan Medical Center
Phase 2 Unknown
NCT05009927 2023-09-01
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)
Centre Leon Berard
Phase 2 Recruiting
NCT00161213 2023-08-14
Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer
Rutgers, The State University of New Jersey
Phase 2 Completed
NCT00764595 2023-07-21
GISTs
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase 2 Completed
NCT00287105 2023-05-24
ESPHALL
Rennes University Hospital
Phase 2 Completed
NCT00323063 2023-03-29
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT01005914 2023-01-06
Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT02712112 2023-01-04
A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs
Asan Medical Center
Phase 2 Completed
NCT01319981 2022-09-27
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03023046 2022-07-13
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
University of Washington
Phase 2 Completed
NCT02461849 2022-06-15
Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy
Samsung Medical Center
Phase 2 Unknown
NCT03170180 2022-06-15
Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer
Samsung Medical Center
Phase 2 Completed
NCT00769327 2022-01-04
CML0408
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT00210119 2021-11-08
AFR22
Institut Bergonié
Phase 2 Terminated
NCT04933669 2021-10-12
ZJGIST-01
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT04883125 2021-05-12
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment
Mansoura University
Phase 2 Completed
NCT03688568 2021-02-12
Study of Imatinib in Children With Neurofibromatosis and Airway Tumors
Indiana University
Phase 2 Withdrawn
NCT02303899 2021-01-22
Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma
Istituto Clinico Humanitas
Phase 2 Completed
NCT02638428 2020-03-19
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Phase 2 Unknown
NCT00509093 2020-03-17
Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00036738 2020-01-29
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00338728 2020-01-27
Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02495519 2020-01-14
A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)
Yonsei University
Phase 2 Completed
NCT02685046 2019-10-14
ImPACCT
UMC Utrecht
Phase 2 Terminated
NCT02177825 2019-04-08
Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas
St. Justine's Hospital
Phase 2 Terminated
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT00045669 2019-02-15
Imatinib Mesylate in Treating Patients With Salivary Gland Cancer
University Health Network, Toronto
Phase 2 Completed
NCT00458848 2019-02-15
LAL0904
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT02709083 2018-11-02
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
Emory University
Phase 2 Terminated
NCT00027586 2018-10-31
Imatinib Mesylate in Treating Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00038649 2018-10-09
Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00415857 2018-08-21
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00882206 2017-12-28
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT01312818 2017-12-28
Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated